Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 235-241

  Kajii, M ^a   Suzuki, C ^a   Kashihara, J ^a   Kobayashi, F ^a   Kubo, Y ^a   Miyamoto, H ^a   Yuuki, T ^a   Yamamoto, T ^b   Nakae, T ^a  

^a Benesis Corporation   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bleomycin induced fibrosis; Immunomodulatory action; Intravenous immunoglobulin

Indexed keywords

BLEOMYCIN; COLLAGEN; IMMUNOGLOBULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCLERODERMA;

ANIMALS; BLEOMYCIN; CHEMOKINE CCL2; COLLAGEN; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGES; MICE; MICE, INBRED C3H; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78650954508     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04295.x     Document Type: Article

References (19)

1. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006; 5:465-70.
2. Ihn H, Mimura Y, Yazawa N et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 2007; 156:1058-60.
3. Levy Y, Amital H, Langevitz P et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004; 50:1005-7.
4. Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001; 124:282-9.
5. Sugihara T, Sekine C, Nakae T et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum 2007; 56:1304-14.
6. Shintani N, Nakajima T, Okamoto T, Kondo T, Nakamura N, Mayumi T. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen Pharmacol 1998; 31:477-81.
7. Vani J, Elluru S, Negi V-S et al. Role of natural antibodies in immune homeostasis: IVIG perspective. Autoimmun Rev 2008; 7:440-4.
8. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999; 92:6-13.
9. Matsushita M, Yamamoto T, Nishioka K. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 2005; 139:429-38.
10. Lakos G, Takagawa S, Varga J. Animal models of scleroderma. Method Mol Med 2004; 102:377-93.
11. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292:535-41.
12. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-8.
13. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006; 297:333-44.
14. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. The Lancet 2006; 367:1683-91.
15. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006; 140:345-56.
16. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. Invest Dermatol 2003; 121:510-6.
17. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000; 15, 164:6174-9.
18. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, Dipietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006; 126:1900-8.
19. Chujo S, Shirasaki F, Kondo-Miyazaki M, Ikawa Y, Takehara K. Role of Connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol 2009; 220:189-95.